SCHEMBL7357013

SCHEMBL7357013

CCCCOC(=O)NOCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.58
TSHR P16473 2/20 0.58
L3MBTL1 Q9Y468 2/20 0.58
ALDH1A1 P00352 2/20 0.58
CYP3A4 P08684 1/20 0.58
MAPK1 P28482 1/20 0.58
NPC1 O15118 6/20 0.51
RAB9A P51151 6/20 0.51
SMN1; SMN2 Q16637 5/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C19 P33261 1/20 0.51
GAA P10253 1/20 0.49
CTSK P43235 2/20 0.48
LMNA P02545 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
RECQL P46063 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1349741 0.84 NPC1 (0.57) ALDH1A1NPC1RAB9ASMN1; SMN2GAA
SCHEMBL12094458 0.84 ITGB3 (0.51) NPC1RAB9ASMN1; SMN2LMNACA12
SCHEMBL27711878 0.82 ALDH1A1 (0.52) TDP1TSHRL3MBTL1ALDH1A1CYP3A4
Hydrochloric Acid SCHEMBL1829485 0.82 ITGB3 (0.50) NPC1RAB9ASMN1; SMN2LMNACA12
SCHEMBL28694494 0.82 ALDH1A1 (0.52) TDP1TSHRL3MBTL1ALDH1A1CYP3A4
SCHEMBL7764162 0.82 CA12 (0.65) TDP1L3MBTL1ALDH1A1MAPK1NPC1
SCHEMBL17384116 0.82 SLC6A5 (0.45) CYP3A4NPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL4649681 0.81 CA12 (0.56) TDP1TSHRL3MBTL1ALDH1A1CYP3A4
SCHEMBL30761916 0.80 HTT (0.52) TDP1TSHRL3MBTL1ALDH1A1CYP3A4
Carbamic Acid SCHEMBL789060 0.80 CYP3A4 (0.50) TDP1TSHRL3MBTL1ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6310095-B1 INHIBITING OR TREATING CANCER, TREATING INTIMAL HYPERPLASIA ASSOCIATED WITH RESTENOSIS AND ATHEROSCLEROSIS, INHIBITING POST-TRANSLATIONAL MODIFICATION OF ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE AND/OR GERANYLGERANYLTRANSFERASE UNIVERSITY OF PITTSBURGH 2001-10-30 US disclosed
EP-0846127-A1 ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY Novartis AG (CH) 1998-06-10 EP disclosed
WO-1997008193-A1 ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY NOVARTIS AG (CH) 1997-03-06 WO disclosed